Ara Metjian, MD
Hematology
Locations
Practice Locations
UCHealth Hematology Clinic - Anschutz Medical Campus
1665 Aurora Ct, 2nd Floor, Anschutz Cancer Pavilion, Aurora, CO 80045720-848-0300
UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave Aurora, CO 80045720-848-0000
Provider Expertise
Care Philosophy
In order to provide the best-level of care, exquisite attention to detail is needed, as there are many factors that are often overlooked or disregarded in patients with bleeding or thrombotic disorders. I strive to know these facts about a patient's history so that clinically relevant information is not missed.
Specialties
- Hematology
Conditions & Treatments
-
Blood / Lymphatic System
Bleeding Disorders, Blood Disorders, Clotting Disorders
Education & Training
Medical Schools
MD, Drexel University College of Medicine (2001)
Undergraduate Schools
BA, Bucknell University (PA) (1995)
Internships
University of North Carolina at Chapel Hill Program (2001)
Residency Program
University of North Carolina at Chapel Hill Program (1999)
Fellowships
University of Pennsylvania Program (2005)
Duke University Hospital Program (2008)
Professional Memberships
American Society for Apheresis, Member
American Society of Hematology, Member
International Society of Thrombosis and Hemostasis, Member
Research & Grants
Research Interests for Patients
I have an active interest in all aspects of Benign Hematology, particularly in congenital bleeding disorders and acquired diseases of hemostasis, such as thrombotic microangiopathies and immune-mediated cytopenias. These conditions are rare and often occur in under-represented populations, which makes their research and development even more necessary. By offering a wide array of clinical trials for these disease states, we can move care forward and offer improved therapies
information for referring providers
Referral Contact Phone
720-848-0300
Referral Contact Fax
720-848-1786
Research Interest for Referring Providers
My research interests run the entire gamut of Benign Hematology, particularly as many of these conditions are uncommon or rare, and often enough, under-represented. By bringing clinical trials to these patients, this is a way to improve care for our patients.